MedTrace Logo

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

NCT03272633 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-06-26

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia in Remission
  • Hematopoietic Cell Transplantation Recipient
  • JAK2 Gene Mutation
  • Loss of Chromosome 17p
  • Mantle Cell Lymphoma
  • Minimal Residual Disease
  • Myelodysplastic Syndrome
  • Non-Hodgkin Lymphoma
  • Plasma Cell Myeloma
  • RAS Family Gene Mutation
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Hematologic Malignancy
  • Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Therapy-Related Acute Myeloid Leukemia
  • Therapy-Related Myelodysplastic Syndrome
  • TP53 Gene Mutation

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Receive IHC

BIOLOGICAL

Irradiated Allogeneic Cells

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Roger Strair · Rutgers Cancer Institute of New Jersey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2022-06-30
Completion
2022-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272633 on ClinicalTrials.gov